NASDAQ : AGMB
AgomAb Therapeutics NV — Financial statements
Healthcare · Biotechnology · Belgium
Last price 7.49 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 368.87M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in EUR.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2019 | |
|---|---|---|---|---|---|---|
| Cost of Revenue | 2.89M | |||||
| Gross Profit | -2.89M | |||||
| Selling, General & Admin | 18.28M | 12.79M | 10.13M | 6.10M | 4.51M | 200.41K |
| Research & Development | 49.82M | 48.88M | 39.31M | 26.31M | 19.42M | |
| Other Operating Expenses | -2.16M | -2.39M | -1.42M | -1.22M | -1.30M | 133.00 |
| Operating Expenses | 65.94M | 59.27M | 48.02M | 31.19M | 22.63M | 200.54K |
| Operating Income | -65.94M | -59.27M | -48.02M | -31.19M | -22.63M | -3.09M |
| Interest Expense | -200.00K | -60.00K | -67.00K | -31.00K | -45.00K | -42.75K |
| Interest & Investment Income | 4.50M | 1.61M | 1.22M | 245.00K | 71.00K | 27.50K |
| Currency Exchange Gain (Loss) | -57.00K | -57.00K | -231.00K | 7.00K | -86.00K | |
| Other Non Operating Income (Expenses) | -4.95M | -4.76M | 838.00K | 18.96M | 11.89M | |
| Pretax Income | -66.65M | -62.55M | -46.26M | -12.01M | -10.81M | -3.10M |
| Income Tax Expense | 4.00K | -619.00K | -2.66M | -53.05K | ||
| Net Income | -66.65M | -62.55M | -46.27M | -11.39M | -8.14M | -3.05M |
| Preferred Dividends & Other Adjustments | 14.95M | 14.95M | 11.68M | 7.89M | 5.42M | |
| Net Income to Common | -81.60M | -77.50M | -57.95M | -19.28M | -13.56M | -3.05M |
| Shares Outstanding (Basic) | 20.65M | 541.13K | 541.13K | 541.13K | 541.12K | |
| Shares Outstanding (Diluted) | 20.65M | 541.13K | 541.13K | 541.13K | 541.12K | |
| EPS (Basic) | -3.95 | -143.22 | -107.09 | -35.63 | -25.07 | |
| EPS (Diluted) | -3.95 | -143.22 | -107.09 | -35.63 | -25.07 | |
| Free Cash Flow | -56.73M | -51.74M | -47.50M | -24.59M | -18.97M | |
| Free Cash Flow Per Share | -2.75 | -95.62 | -87.78 | -45.45 | -35.05 | |
| EBITDA | -65.56M | -58.87M | -47.97M | -31.09M | -22.61M | |
| D&A For EBITDA | 380.67K | 402.67K | 56.00K | 99.00K | 23.00K | |
| EBIT | -65.94M | -59.27M | -48.02M | -31.19M | -22.63M | -3.09M |
Balance sheet
Fiscal year January - December; amounts in EUR.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2019 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 221.59M | 86.42M | 171.46M | 122.40M | 27.67M | 7.33M |
| Short-Term Investments | 30.39M | 30.10M | 40.00M | |||
| Cash & Short-Term Investments | 251.98M | 116.51M | 171.46M | 122.40M | 67.67M | 7.33M |
| Other Receivables | 4.08M | 2.12M | 16.95M | 3.33M | 157.63K | |
| Receivables | 4.08M | 2.12M | 16.95M | 3.33M | 157.63K | |
| Other Current Assets | 6.50M | 638.00K | 267.00K | 121.00K | 85.00K | |
| Total Current Assets | 258.48M | 121.24M | 173.84M | 139.47M | 71.08M | 7.48M |
| Property, Plant & Equipment | 1.41M | 1.59M | 1.99M | 1.61M | 62.00K | |
| Goodwill | 8.61M | 8.61M | 8.61M | 8.61M | 8.61M | |
| Other Intangible Assets | 20.11M | 20.11M | 20.11M | 20.11M | 20.11M | |
| Other Long-Term Assets | 2.31M | 2.16M | 1.80M | 1.46M | 1.13M | |
| Total Assets | 290.92M | 153.71M | 206.36M | 171.26M | 101.00M | 7.48M |
| Accounts Payable | 11.84M | 7.63M | 5.95M | 6.83M | 3.90M | |
| Accrued Expenses | 2.72M | 2.10M | 1.47M | 699.00K | ||
| Current Portion of Leases | 229.00K | 249.00K | 273.00K | 181.00K | 26.00K | |
| Current Unearned Revenue | 1.26M | 1.46M | 801.00K | 1.18M | 1.78M | |
| Other Current Liabilities | 6.74M | 6.53M | 1.23M | 23.32M | ||
| Total Current Liabilities | 20.07M | 18.59M | 9.13M | 10.88M | 29.72M | |
| Long-Term Leases | 910.00K | 1.00M | 1.27M | 1.44M | 36.00K | |
| Long-Term Deferred Tax Liabilities | 622.00K | |||||
| Other Long-Term Liabilities | 3.44M | 3.21M | 7.88M | 7.50M | 4.37M | 864.22K |
| Total Liabilities | 25.55M | 22.80M | 18.28M | 19.82M | 34.75M | 864.22K |
| Common Stock | 304.62M | 25.00K | 25.00K | 25.00K | 25.00K | 10.18M |
| Retained Earnings | -212.62M | -181.65M | -119.10M | -72.83M | -61.44M | -3.56M |
| Comprehensive Income & Other | 427.00K | 12.84M | 7.47M | 6.62M | 4.91M | |
| Total Common Equity | 92.43M | -168.78M | -111.60M | -66.19M | -56.51M | 6.62M |
| Shareholders' Equity | 265.38M | 130.90M | 188.08M | 151.44M | 66.25M | 6.62M |
| Total Liabilities & Equity | 290.92M | 153.71M | 206.36M | 171.26M | 101.00M | 7.48M |
| Total Debt | 1.14M | 1.25M | 1.54M | 1.62M | 62.00K | |
| Net Cash (Debt) | 250.84M | 115.26M | 169.91M | 120.78M | 67.61M | 7.33M |
| Net Cash Per Share | 12.15 | 213.00 | 314.00 | 223.20 | 124.94 | |
| Filing Date Shares Outstanding | 40.76M | 49.25M | 541.12K | 541.12K | 541.12K | |
| Total Common Shares Outstanding | 40.76M | 49.25M | 541.12K | 541.12K | 541.12K | |
| Working Capital | 238.41M | 102.65M | 164.72M | 128.59M | 41.37M | 7.48M |
| Book Value Per Share | 2.27 | -3.43 | -206.24 | -122.32 | -104.43 | |
| Tangible Book Value | 63.71M | -197.50M | -140.32M | -94.91M | -85.23M | 6.62M |
| Tangible Book Value Per Share | 1.56 | -4.01 | -259.32 | -175.40 | -157.50 | |
| Machinery | 320.00K | 316.00K | ||||
| Leasehold Improvements | 359.00K | 359.00K |
Cash flow statement
Fiscal year January - December; amounts in EUR.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2019 | |
|---|---|---|---|---|---|---|
| Net Income | -66.65M | -62.55M | -46.27M | -11.39M | -8.14M | |
| Depreciation & Amortization | 197.00K | 219.00K | 311.00K | 99.00K | 23.00K | |
| Stock-Based Compensation | 5.22M | 5.36M | 1.07M | 2.16M | 2.21M | |
| Other Operating Activities | 2.52M | 4.83M | -661.00K | -19.58M | -14.47M | |
| Change in Accounts Payable | 4.05M | 2.36M | -230.00K | 3.69M | 2.95M | |
| Change in Unearned Revenue | 434.00K | 747.00K | -395.00K | -580.00K | 1.45M | |
| Change in Other Net Operating Assets | -2.50M | -2.70M | -657.00K | 1.01M | -2.99M | |
| Operating Cash Flow | -56.73M | -51.74M | -46.83M | -24.59M | -18.97M | |
| Capital Expenditures | -4.00K | -4.00K | -675.00K | |||
| Cash Acquisitions | -3.00M | -4.59M | ||||
| Investment in Securities | -30.00M | -30.00M | 40.00M | -40.00M | ||
| Investing Cash Flow | -30.00M | -33.00M | -675.00K | 40.00M | -44.59M | |
| Long-Term Debt Issued | 135.00K | |||||
| Long-Term Debt Repaid | -338.00K | -163.00K | -100.00K | -717.00K | ||
| Lease Payments | -339.00K | -338.00K | -163.00K | -100.00K | -26.00K | |
| Net Debt Issued (Repaid) | -339.00K | -338.00K | -163.00K | -100.00K | -582.00K | |
| Issuance of Common Stock | 163.96M | 97.06M | 79.87M | 38.38M | ||
| Other Financing Activities | 1.27M | -130.00K | -447.00K | -171.00K | ||
| Financing Cash Flow | 164.90M | -338.00K | 96.76M | 79.32M | 37.63M | |
| Foreign Exchange Rate Adjustments | 45.00K | 45.00K | -204.00K | |||
| Net Cash Flow | 78.21M | -85.04M | 49.05M | 94.73M | -25.92M | |
| Free Cash Flow | -56.73M | -51.74M | -47.50M | -24.59M | -18.97M | |
| Free Cash Flow Per Share | -2.75 | -95.62 | -87.78 | -45.45 | -35.05 | |
| Levered Free Cash Flow | -24.37M | -16.51M | -49.90M | |||
| Unlevered Free Cash Flow | -24.33M | -16.47M | -49.88M | |||
| Free Cash Flow After Leases | -57.07M | -52.08M | -47.67M | -24.69M | -18.99M | |
| Cash Interest Paid | 96.00K | 69.00K | 10.00K | 20.00K | 44.00K | |
| Cash Income Tax Paid | 4.00K | 3.00K | 2.00K | |||
| Change in Working Capital | 1.98M | 406.00K | -1.28M | 4.12M | 1.41M |
Ratios
Fiscal year January - December; amounts in EUR.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2019 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 368.87M | |||||
| Enterprise Value | 82.29M | |||||
| Debt / Equity Ratio | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | |
| Net Debt / Equity Ratio | -0.94 | -0.88 | -0.90 | -0.80 | -1.02 | -1.11 |
| Net Debt / EBITDA Ratio | 3.83 | 1.96 | 3.54 | 3.88 | 2.99 | |
| Net Debt / FCF Ratio | 4.42 | 2.23 | 3.58 | 4.91 | 3.56 | |
| Quick Ratio | 12.55 | 6.49 | 19.02 | 12.80 | 2.39 | |
| Current Ratio | 12.88 | 6.52 | 19.05 | 12.81 | 2.39 | |
| Return on Equity (ROE) | -39.22% | -27.26% | -10.46% | -90.33% | ||
| Return on Assets (ROA) | -20.58% | -15.90% | -14.32% | -49.38% | ||
| Return on Capital Employed (ROCE) | -24.30% | -43.90% | -24.30% | -19.40% | -31.80% | -41.30% |
| Buyback Yield / Dilution | -3,716.54% | 0.00% |